US President Joe Biden’s administration is considering the cancelation of arms deals with Saudi Arabia that pose human rights concerns while limiting military sales to “defensive” weapons, as it reassesses it relationship with the kingdom.
Four sources familiar with the US administration’s thinking said that after pausing US$500 million in arms deals with Saudi Arabia out of concern over casualties in Yemen earlier this year, officials are assessing the equipment and training included in recent sales to determine what can be considered defensive.
Those deals would be allowed.
Photo: AFP
“Our focus is on ending the conflict in Yemen even as we ensure Saudi Arabia has everything it needs to defend its territory and its people,” a US Department of State spokesperson said, adding that Biden has pledged to end US military support for the military campaign against the Houthi rebels in Yemen.
The Biden administration is recalibrating its relationship with Saudi Arabia, a country with which it has severe human rights concerns, but which is also one of Washington’s closest US allies in countering the threat posed by Iran.
“They’re trying to figure out where do you draw the lines between offensive weapons and defensive stuff,” one congressional aide familiar with the issue said, describing the process.
Sales of products deemed defensive — such as Terminal High Altitude Area Defense anti-ballistic missile defense systems made by Lockheed Martin or Patriot missile defense systems made by Lockheed and Raytheon — would still be allowed under such new policy.
However, it would end big-ticket deals — for products such as precision-guided munitions and small-diameter bombs — like those brokered under former US president Donald Trump in the face of strong objections from members of the US Congress.
After he lost the US presidential election on Nov. 3 last year, Trump’s State Department kept approving weapons sales that could be considered offensive.
The weapons review also affects deals with the United Arab Emirates (UAE).
On Jan. 20, the day that Trump left office and Biden became president, the UAE signed agreements with the outgoing administration to buy up to 50 F-35 jets, 18 armed drones and other defense equipment in a deal worth US$23 billion.
The COVID-19 variant discovered in South Africa can “break through” Pfizer-BioNTech’s COVID-19 vaccine to some extent, a real-world data study released on Saturday found, although its prevalence in the country is low and the research has not been peer reviewed. The study in Israel compared almost 400 people who had tested positive for COVID-19, 14 days or more after they received one or two doses of the vaccine, against the same number of unvaccinated people with the disease. It matched age and gender, among other characteristics. The South African variant, B.1.351, was found to make up about 1 percent of all the COVID-19
RARE ADMISSION: A top Chinese expert was the first to publicly address the efficacy of the nation’s vaccines as it aims to inoculate 40 percent of its population by June China is considering mixing different COVID-19 vaccines to improve the relatively low efficacy of its existing options, a top health expert told a conference in Chengdu on Saturday. Authorities have to “consider ways to solve the issue that efficacy rates of existing vaccines are not high,” Chinese media outlet The Paper reported, citing Chinese Center for Disease Control and Prevention Director Gao Fu (高福). His comments mark the first time a top Chinese expert has publicly alluded to the relatively low efficacy of the country’s vaccines, as China forges ahead in its mass vaccination campaign and exports its jabs around the world. China
The Australian government yesterday said that it had decided against buying the single-dose Johnson & Johnson (J&J) COVID-19 vaccine and identified a second case of a rare blood clot likely linked to the AstraZeneca shot. The Australian government had been in talks with the New Jersey-based pharmaceutical giant, which had asked the Australian Therapeutic Goods Administration for provisional registration. However, Australian Minister of Health Greg Hunt ruled out a J&J contract, because its vaccine was similar to the AstraZeneca product, which Australia had already contracted for 53.8 million doses. Hunt said the government was following the advice of Australia’s scientific and technical advisory
The Indonesian government has said it is satisfied with the effectiveness of the Chinese COVID-19 vaccine it has been using, after China’s top disease control official said that current vaccines offer low protection against the novel coronavirus. Siti Nadia Tarmizi, a spokesperson for Indonesia’s COVID-19 vaccine program, on Monday said the WHO had found that the Chinese vaccines had met requirements by being more than 50 percent effective. Clinical trials in Indonesia for the vaccine from Chinese drugmaker Sinovac showed that it was 65 percent effective, she said. “It means ... the ability to form antibodies in our bodies is still very
RSS